Drug Profile
TGFK 08AA
Alternative Names: TGFK08AA; TGFK08AA-ER; TGFK08AA-IRLatest Information Update: 08 Jan 2016
Price :
$50
*
At a glance
- Originator Unknown
- Developer Fabre-Kramer Pharmaceuticals
- Class
- Mechanism of Action 5-HT1A serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Generalised anxiety disorder
Most Recent Events
- 08 Jan 2016 Phase-II development for Generalised anxiety disorder is ongoing in USA (PO, controlled release)
- 15 Jul 2010 Phase-II clinical trials in Generalised anxiety disorder in USA prior to July 2010 (PO, controlled-release & PO, immediate-release)